Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02091141
Recruitment Status : Recruiting
First Posted : March 19, 2014
Last Update Posted : February 5, 2020
Information provided by (Responsible Party):
Genentech, Inc.